Tevimbra(Tislelizumab)

Inquiry / Price
  • Model Number:
    RL2320301801
  • Brand Name:
    百泽安 (Tevimbra)
  • Origin:
    Original invention from China
  • Small Orders:
    Small batches also available
  • Tags:
Inquire Now Link

Poster
  • Details
  • Description
  • Packaging Size
    1Bottle/Box
  • Strength
    10ml:100mg
  • Compositon
    Tislelizumab
  • Treatment
    Esophageal Cancer
  • Form
    Injection
  • Brand
    百泽安 (Tevimbra)
  • Quantity Unit
    10ml:100mg/Bottle/Box
  • Manufacturer
    BeiGene Biotechnology,china

Tevimbra (Tislelizumab-jsgr) sold under the brand name 百泽安 in china, is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene’s immuno-oncology biologic program, and we believe it could serve as a key element of our immuno-oncology combination platform. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.


Link

Poster

Top